Brooklyn ImmunoTherapeutics EBIT

The latest EBIT for BTX is $-19M as of September 2024. That compares with $-19M in the prior-year period — up 3.8% year over year. That is below the Telecommunications sector average of $190B. Investors often review this figure alongside Brooklyn ImmunoTherapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, BTX's EBIT moved from $-19M to $-19M — a 3.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Brooklyn ImmunoTherapeutics's operating scale or balance-sheet position.

Against Telecommunications companies, BTX currently prints $-19M for EBIT, while the sector average sits near $190B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Brooklyn ImmunoTherapeutics's growth, margins, and balance sheet.

A EBIT figure of $-19M for BTX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Telecommunications average is about $190B. Explore the charts below for those layers of context.

After noting BTX's EBIT ($-19M), review year-over-year change from $-19M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.